Chronic inflammatory diseases are the most significant cause of death in the world with the World Health Organization (WHO) ranking chronic inflammatory diseases as the greatest threat to human health. Despite the widespread use of corticosteroids and the availability of biologicals, there remains a significant unmet medical need for novel anti-inflammatory drugs in the treatment of chronic inflammatory diseases. Current therapies often fail to provide adequate long-term disease control or are associated with substantial side effects, underscoring the importance of developing more targeted and safer therapeutic options.

sterna biologicals is the only company that has successfully made GATA-3 druggable and clinically demonstrated that the downregulation of GATA-3 could provide for a truly novel, first-in-class, non-steroidal, anti-inflammatory therapy.